Pipeline

Our cell therapy product candidate pipeline is comprised of first-in-class cellular immunotherapies for cancer and immune disorders. Our programs reflect our dedication and commitment to pioneering ground breaking science to address severe, life-threatening diseases where the unmet need is significant and the treatment options are limited.
Product Cell Type Description Indication R&D PreClinical Clinical Collaboration
iPSC-derived, Off-the-Shelf Cell Products
FT500 iPSC-NK iNK Cell +CPB in Solid Tumors

FT516 iPSC-NK hnCD16 iNK Cell +mAb in Hematologic Malignancies

FT596 iPSC-NK CAR19 + hnCD16 + IL15/R iNK Cell Hematologic Malignancies

FT538 iPSC-NK CD38-less + hnCD16 + IL15/R iNK Cell +anti-CD38 mAb in Multiple Myeloma

FT819 iPSC-T TCR-less, TRAC-Targeted CAR19 iT Hematologic Malignancies

FT5xx iPSC-NK Multi-faceted engineered attributes Solid Tumors

FT8xx iPSC-T Multi-faceted engineered attributes Hematologic Malignancies

ONO Pharmaceutical
FT8xx iPSC-T Multi-faceted engineered attributes Solid Tumors

ONO Pharmaceutical
FT301 iPSC-MDSC Engineered immuno-suppresive attributes Not disclosed

Donor-derived Cell Products
ProTmune™ Hematopoietic graft Allogeneic mPB cell graft Hematologic Malignancies

NK100 NK Adaptive Memory NK Cells AML

NK100 NK Adaptive Memory NK Cells Ovarian Cancer

NK100 NK Adaptive Memory NK Cells +/- mAb in Solid Tumors